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Women taking Adjuvant Endocrine Therapies (AET) following early-stage breast cancer 
 
Abstract: 
Objectives: To evaluate the Beliefs about Medicine Questionnaire to explore adherence to 
adjuvant endocrine therapy after treatment for breast cancer (BMQ-AET). Method: Factor 
structure of the BMQ-AET was explored alongside internal consistency, convergent validity 
and acceptability. Results: The BMQ-AET Specific Scale fitted the original 10 item model. 
Internal consistency of the BMQ-AET was much improved compared to the original BMQ 
and convergent validity showed predicted direction of correlation, although correlation with 
BMQ-AET concerns scale was low. Acceptability was good. Conclusions: The evaluation 
of the BMQ-AET is encouraging, and could facilitate future research around adherence to 
AET. 
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Background: 
Approximately 80% of breast cancers will be oestrogen receptor positive, and adjuvant endocrine 
therapy (AET) such as Tamoxifen and Aromatase Inhibitors are recommended (Keen & Davidson, 
2003). Adjuvant endocrine therapy taken for five years to ten years has proven effectiveness in 
preventing recurrence and decreasing mortality from breast cancer(Davies et al., 2013, Gray, 2013, 
Dowsett et al., 2009, ATAC group, 2008, Howell et. al., 2005, Coombes et. al., 2004, Goss et. al., 
2003, Fisher et. al., 1996). However, to gain these potential benefits women need to adhere to the 
medication as prescribed, and reported rates of non-adherence are relatively high. Reviews report 
that 10-50% of women either do not take the correct dosage at the prescribed frequency or 
discontinue therapy leading to a 20% increase in mortality(Makubate et al., 2013, McCowan et al., 
2008, Banning, 2012, Gotay & Dunn, 2011, Hadji, 2010, Chlebowski & Geller, 2006). 
Beliefs about medications as factors influencing patient adherence behaviour have been reported in 
various clinical groups(van-Dulmen et.al., 2007). Investigating women’s beliefs about endocrine 
therapies is crucial to explore their perception of risk and perception of benefit from taking the 
medication, and develop interventions to improve adherence. 
The BMQ has been tested in a wide variety of patient populations and is a valid and reliable measure 
of medication beliefs(Horne & Weinman, 1999). A recent meta-analytic review reports that across 
studies, higher adherence was associated with stronger perceptions of necessity of treatment, OR = 
1.742, 95% CI [1.569, 1.934], p<0.0001, and fewer Concerns about treatment, OR = 0.504, 95% CI: 
[0.450, 0.564], p<0.0001. These relationships remained significant when data were stratified by 
study size, the country in which the research was conducted and the type of adherence measure 
used(Horne et al, 2013). While it has been used to assess the beliefs and perceptions of women 
taking endocrine therapy after breast cancer(Corter et. al., 2013, Wouter et. al., 2013, Grunfeld et 
al., 2005), and in other cancers (Llewellyn McGurk Weinman, 2005, Llewellyn McGurk Weinman, 
2007), no psychometric evaluation of this measure for this population has been reported. 
The BMQ-AET adapted wording of the BMQ Specific Concerns and BMQ Specific Necessity items to 
be more relevant to women taking AET following breast cancer. The current study aims to evaluate 
the factor structure, internal consistency, and acceptability of the BMQ-AET Specific scale in a 
sample of women prescribed AET for breast cancer. 
Methods and Procedures: 
Design: 
A cross-sectional study was carried out to explore women’s experiences of AET. As part of this study, 
women completed the BMQ-AET within a self-report postal questionnaire. 
Sample: 
Participants included women aged 36-85 years taking adjuvant endocrine therapy following 
treatment for breast cancer. These women had previously participated in the Joint Aches Cohort 
Study (JACS) looking at women’s experiences of joint aches, pain and stiffness in breast 
cancer(Fenlon et al., 2014). During JACS, participants were asked to indicate their willingness to 
participate in future studies; we re-approached only this subsample for this adherence study. All 
participants had been diagnosed with primary oestrogen receptive positive breast cancer, and had 
been prescribed adjuvant endocrine therapy. Exclusion criteria included: women with more 
advanced cancer, women seriously ill with other conditions, and women who had a poor 
comprehension of English. 
Procedure: 
Ethical approval was gained from the University Research Ethics Committee (UREC). Informed 
consent was gained, and postal questionnaires were sent out in July 2014, with a reminder sent after 
3 weeks of non-response. Participants took approximately 20 minutes to complete the 
questionnaire, which include a range of nominal and multiple choice questions asking about their 
experiences of taking AET, and two scales: the Medical Adherence Rating Scale (MARS)(Thompson 
Kulkami Sergejew, 2000) and the BMQAET Specific scales. 
Measures: 
The Beliefs about Medicines Questionnaire (BMQ) was originally developed to aid understanding of 
people’s perception of medicine regimes, and to help understand adherence to medication. It is an 
18 item self-report measure of beliefs about medicine (Horne & Weinman, 1999) derived from a 
pool of items representing commonly held beliefs about medication in a chronic illness sample 
(Asthmatic, Cardiac, Diabetic, Renal, Psychiatric, and General)(Horne & Weinman, 1999). Specific (10 
items) and General (8 items) beliefs were analysed separately. The measure comprises two sections, 
each divided into two subscales. The BMQ-Specific comprises two five item subscales: the ‘Specific 
Necessity’ subscale (i.e. beliefs about the necessity of taking that specific medication to remain 
healthy) and the ‘Specific Concerns’ subscale (i.e. concerns about the negative effects of taking that 
specific medication). The BMQ-General comprises two 4-item subscales assessing beliefs that 
medicines are harmful which should not be taken continuously (General-Harm) and that medicines 
are overused by doctors (General- Overuse). All items of the BMQ are rated on a 5-point likert scale 
where 1 represents strongly agree, and 5 represents strongly disagree. Scores obtained for the 
individual items are summed to give a total score for each subscale, and the two sections of the 
BMQ can be used in combination or separately. 
Table 1 identifies the modifications made to the original BMQ for the BMQ-AET. The term ‘hormone 
treatment’ is used instead of AET, as the former is a more recognised terminology for this treatment 
among women. Changes were made in consultation with service users and the expert advisory team 
for this study that included a breast cancer surgeon, an oncologist, a GP, a health psychologist, a 
professor of cancer nursing, and a medical sociologist. Most items had minor changes to make the 
items relevant to the population. However, the item ‘my life would be impossible without medicines’ 
was changed to ‘taking hormone treatment makes me feel I am taking positive steps to remain well’ 
because AET is not taken by women to reduce side effects of a condition, but to reduce the risk of 
recurrence of breast cancer and is therefore not relevant to this new population. AET can often 
cause side effects that make it difficult to continue with the treatment and therefore adherence is 
more related to taking personal control to avoid the return of a condition rather than controlling a 
pre-existing condition; this factor was not covered elsewhere and so deemed a relevant replacement 
item. 
Service users from Independent Cancer Patients’ Voice (n=2), cancer experts (n=4), and a 
representative from the charity Breast Cancer Care evaluated the face validity of the modified items 
during the development of the questionnaire, with minor adjustment to the final wordings made to 
ensure comprehension. As items on the General beliefs subscale are not condition specific, it was 
not necessary to amend wording. 
The Medical Adherence Report Scale (MARS-5) (Thompson 2000) assesses adherence to treatment 
and was used to provide a measure of convergent validity with the BMQ-AET. 
The MARS-5 consists of five general statements about suboptimal adherence behaviour (I forget to 
take my AET medicine, I alter the dose of my AET medicine, I stop taking my AET medicine for a 
while, I decide to skip one of my AET tablets, I take AET less than prescribed) answered on a 5 point 
scale where 1 represents ‘always’, and 5 represents ‘never’. Items were not summed but used 
individually in determining types of adherence and non-adherence. 
Analysis: 
COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) were 
used in the selection of evaluation methods for the analysis (Mokkink et al., 2010). Principal 
Components Analysis (PCA) using direct oblimin rotation was used to explore the factor structure of 
the modified measure. PCA was chosen over factor analysis because it offers a more pragmatic 
psychometric solution, reducing the number of observed variables to a smaller number of 
components (factors) which account for most of the observed variance, thus avoiding some of the 
potential problems of factor interdependency which are associated with other types of psychometric 
scale development methods(Bartholomew, 2002). Furthermore, this method mirrors that used in 
the development and evaluation of the original BMQ(Horne & Weinman, 1999) and it was our 
intention to be able to compare across these two versions. 
The resultant factors were subjected to internal consistency testing using Cronbach’s alpha tests. 
Convergent validity was explored by comparing correlation between the BMQ-AET and MARS; due 
to non-parametricity of MARS data, Spearman’s correlation tests were used. 
Acceptability was examined by exploring missing data, floor/ceiling effects, and face validity was 
assessed through discussions with service users and clinicians during the development stage of the 
questionnaire. 
Results: 
Questionnaires were returned by 211 women (73%), all of whom completed the BMQ-AET scale and 
206 completed the MARS. The socio-demographic characteristics and health status of responders 
are summarised in table 2: Factor Analysis 
Standard diagnostic tests were run to ensure that the data were suitable for factor analysis. 
Both the Kaiser-Meyer-Olkin test of sampling adequacy (KMO=.791) and Bartlett's test of sphericity 
(p = <.001) indicated that the current data were indeed appropriate. As is usual practice, an initial 
scree plot analysis was undertaken suggesting a 2 factor solution was the most parsimonious fit for 
the data, and this corresponded with the factor structure of the original BMQ. More recent practice 
has also been to consider a Parallel Analysis Monte Carlo simulation (using randomly generated 
data) to verify the number of required factors(Velicer Eaton Fava, 2000). Using the method 
described by Hayton et al (2004)(Hayton Allen Scarpello, 2004) which employs an upper bound of 
the 95% confidence interval for eigenvalues, averaging across 100 random data sets, this procedure 
confirmed that two resultant factors were appropriate. 
Table 3 shows the factor structure matrix (with Kaiser normalisation) resulting from the principle 
components analysis; this accounted for 56.936 of the total variance (individual factor variances also 
indicated). Where items loaded onto multiple factors, they were retained only for the factor onto 
which they loaded most strongly. 
Analysis indicated that the factor structure of the BMQ-AET-specific items mapped exactly onto the 
factor structure of the original scale; the original subscale names were thus retained whereby Factor 
1 became the concerns subscale, and Factor 2 became the necessity scale. 
Only one item loaded with a very low factor loading (‘Hormone treatment is a mystery to me’: .283) 
with the remainder meeting recommended criteria (Stevens Erlbaum, 1992). The low factor loading 
item was included in the final measure as removing this item did not improve overall psychometric 
properties of the scale, so it was retained to uphold the original structure of the measure. 
Internal consistency 
Cronbach’s alpha’s statistics provide an indication of how well items within a given scale are 
measuring a similar and stable construct. Typically, subscales with a Cronbach’s alpha of less than .7 
are considered inadequate, however, Cortina (1993) notes that the method of calculating this 
statistic is biased by item numbers whereby factors on a scale with fewer items tend usually to 
produce a lower alpha coefficient as a bi-product of the statistical calculation(Cortina, 1993). As our 
two subscales of specific beliefs scored alpha coefficients of .776 and .795 for concerns and necessity 
respectively; even when bearing in mind Cortina’s caution (which is relevant given that only 5 items 
appear in each subscale), these two scales exceed the usual cut-off for acceptability reliability. These 
figures are aligned with, and in some cases exceed, those reported in the confirmatory factor 
analysis reported by Horne et al (1999)(Horne & Weinman, 1999). 
Convergent Validity 
The MARS is a self-report scale of adherence to medication and so provided an adequate measure of 
convergent validity for these data, whereby we would anticipate a negative correlation between 
both specific concerns and adherence, and a positive correlation between specific necessity beliefs 
and adherence. Correlations tests indicated a significant correlation between higher treatment 
necessity beliefs (BMQ-AET Specific Necessity) and greater adherence (MARS) scores (rs= 0.215, 
p=.001). However, correlations between BMQ-AET Specific Concerns and MARS, while showing the 
expected direction of association (higher treatment concern beliefs correlated with lower adherence 
scores), failed to reach statistical significance (rs= -0.038, p=.100). 
Acceptability 
Acceptability of the two individual scales was determined by examining the rate of missing  
responses to each item, as this provides an indicator of how acceptable the instrument is in a given 
population(Fitpztrick et al, 1998). The BMQ-AET was completed by all 211 respondents, with only 5 
cases having missing responses for one or more items. 
Floor and ceiling effects (i.e. the percentage scoring the minimum and maximum score) were 
examined for the BMQ-AET Specific Concerns and the BMQ-AET Specific Necessity. The Specific 
Concerns scale had a 3.4% ceiling effect and a 1% floor effect; The Specific Necessity had a 0% ceiling 
effect and a 8.7% floor effect. As a proportion of up to 15% can be considered a low effect(Terwee et 
al, 2007), the data shows acceptable ceiling and floor effects. 
 
 
 
 
Discussion 
The BMQ-AET was included in a questionnaire survey to explore women’s experiences and views of 
taking AET to identify factors that may be associated with adherence or nonadherence. 
Independent testing of the BMQ for women prescribed AET following breast cancer has not 
previously been reported. The BMQ was modified so the wording was suitable to women who were 
taking AET. The evaluation of the BMQ-AET showed a similar factor structure to the original BMQ 
Specific subscale(Horne & Weinman, 1999), and we report good internal consistency, encouraging 
convergent validity and good acceptability within this sample. The modified scale may therefore 
provide a valuable assessment of women’s specific beliefs around AET. 
The results show all factors had sufficient factor loading to be included and therefore the original 
factor structure proposed by Horne (1999) was retained(Horne & Weinman, 1999). This is an 
important finding as it suggests that the factors represent ‘core themes’ underpinning common 
representations of Specific Beliefs in this population which may generalise out to other specific 
condition groups. One item ‘my life would be impossible without medicines’ was changed to ‘taking 
hormone treatment makes me feel I am taking positive steps to remain well’ because AET is not 
taken by women to reduce side effects of a condition, but to reduce the risk of recurrence of breast 
cancer and is therefore not relevant to this new population. AET can often cause side effects that 
make it difficult to continue with the treatment and therefore adherence is more related to taking 
personal control to avoid the return of a condition rather than controlling a pre-existing condition. 
Although the meaning of the item is slightly different, our psychometric analysis of the scale 
demonstrates that the new item is still correlated with the other cluster items within the factor 
group. As such we would suggest that whilst the new item represents some deviation, it is both a 
pragmatic and psychometrically valid alternation to make the scale relevant to this patient 
population. 
Other studies have reported similar findings in primary care, general medical populations, and 
mental health populations in the UK and across cultures (Salgado et al, 2013, Cuevas et al, 2011, 
Browne et al, 2005). In this study, the only exception to this was the item ‘Hormone treatment is a 
mystery to me’ and so this may require some further investigation in future uses of the scale. 
Internal consistency exceeded that reported by Horne in the original evaluation of the measure, 
which has also been reported in other patient populations, including Stroke and Asthma indicating 
the generalisability of the BMQ (Sjölander Eriksson Glader, 2013, Horne & Weinman, 2002). 
Furthermore, results reported good completion rates, acceptable ceiling and floor effects. Face 
validity of the modified scale was confirmed prior to completion of the questionnaire through 
consultation with service users and health professionals in the advisory group for this study. 
Correlation between BMQ-AET specific subscales and MARS were in the predicted direction, 
although only the association between treatment necessity beliefs and adherence reached 
significance. 
The low correlation between treatment concern beliefs and adherence may have been due to the 
subjective nature of capturing non-adherence on self-reported measures such as the MARS. 
Correlation with objective measures, such as pill counts, may provide a better gold standard in 
future studies. A recent meta-analysis reported significant correlation between both Concerns and 
Necessity in 33 and 31 studies correlating with MARS(Horne et al, 2013). However, they concluded 
that stratifying by long term condition and adherence measurement revealed a need for further 
studies using objective measures in longer term conditions to ensure greater accuracy of measuring 
nonadherence long-term. Furthermore, a larger study may have given greater power to the study at 
which point we may expect these effects to more likely reach statistical significance cut-offs. A 
further meta-analysis exploring associations between the BMQ and different measures of medical 
adherence concluded that they were correlated at a population level and across the majority of 
included conditions(Foot et al, 2015).  
The current work is based on a self-selected sample that may have presented response bias. 
The majority of the sample were white Caucasians, so may not be generalizable to ethnic minority 
groups. While this study reports a correlation between the modified BMQ specific subscales and 
MARS in the predicted direction, more studies, possibly with larger samples may improve the 
statistical power to gain significance in both the BMQ-AET Necessity and the BMQ-AET Concerns. 
Further confirmatory factor analysis is also advised to ensure that this factor structure is retained 
across multiple samples with less exploratory methods of statistical modelling. Additional studies 
investigating the psychometric properties of BMQ in other settings and populations may be 
beneficial to confirm our finding that suggests beliefs provide ‘core themes’ which are not 
necessarily population specific. 
In conclusion, the BMQ-AET for women prescribed AET following breast cancer has good internal 
consistency, encouraging convergent validity and good acceptability for the Specific Beliefs about 
the necessity of and concerns regarding taking AET, and could facilitate future research in this field. 
Women are prescribed AET for between 5 and 10 years after completion of primary cancer 
treatment(Gray, 2013, Davies et al., 2013, Goss et al, 2005) and adherence over the entire course is 
generally low, with consequent increased risk of cancer recurrence and mortality(Makubate et al, 
2013, Hershamn et al, 2010, McCowan et al., 2008, Partridge et al, 2003). Reasons for not adhering 
to AET need to be investigated at an individual and population level. The BMQ-AET evaluated in this 
paper could facilitate a better understanding of factors which affect adherence to AET following 
breast cancer, to help develop interventions to support patients in engaging with this treatment and 
coping with the challenging side effects that might result. 
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 Table  1: Original Specific BMQ (Horne) and Modified Specific BMQ items  for  women taking AET. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original  BMQ Specific Modified BMQ Specific  (BMQ-AET) 
My health at present depends on 
medicines 
My health at present depends on me 
taking  hormone treatment 
Having to take this medicine worries  me Having to take hormone treatment worries 
me 
My life would be impossible without 
medicines 
Taking hormone treatment makes me 
feel  I am taking positive steps to remain  
well 
Without my medicines I would be very  ill Without taking hormone treatment I 
would be more likely to develop breast 
cancer again 
I sometimes worry about the long term 
effects of taking medicines 
I sometimes worry about long term effects 
of taking hormone  treatment 
My medicines are a mystery to  me Hormone treatment is a mystery to  me 
My health in the future is dependent on 
my medicines 
My health in the future will depend on me 
taking  hormone treatment 
My medicines disrupt my  life Taking hormone treatment disrupts my 
life 
I sometime worry about becoming too 
dependent  on medicines 
I sometimes worry about having hormone 
treatment   over a long period of time 
My medicines protect  me from becoming 
worse 
Hormone treatment protects me  from 
becoming ill 
 
 Table  2: Demographics and clinical data (n=211) 
 
 Total 
(N=211) 
Non-adherers 
(N=46) 
Adherers 
(N=165) 
Age    
Range 36 to 85 years   
Median 63 years   
36-50 years 31 (15%) 13 (28%) 18 (11%) 
51-64 years 80 (38%) 19 (41%) 61 (37%) 
≥65 years 87 (41%) 14 (30%) 73 (44%) 
Not provided 13 (6%)   
Marital status    
Married 167 (79%) 37 (80%) 130 (79%) 
Divorced 21 (10%) 3 (7%) 18  (11%) 
Widowed 13 (6%) 2 (4%) 11 (7%) 
Single 10 (5%) 4 (9%) 6  (4%) 
Employment    
status:    
Retired 105 (50%) 17 (37%) 88 (53%) 
Paid work 87 (41%) 23 (14%) 64 (39%) 
Sick leave/unable 9 (4%) 3  (7%) 6  (4%) 
to work    
Unemployed 2 (1%)  2  (1%) 
Other 8 (4%) 3  (7%) 5  (3%) 
Education    
‘0’ level 77 (37%) 15 (33%) 62 (38%) 
‘A’ level 33 (16%) 12 (26%) 21 (13%) 
College/University 37 (18%) 7 (15%) 30 (18%) 
Post-graduate 24 (11%) 7 (15%) 17 (10%) 
Other 32 (15%) 5 (11%) 35 (21%) 
Not provided 8 (4%)   
Ethnic    
background:    
White British 207 (98%) 46 (100%) 161 (98%) 
Other 3 (2%)  3 (2%) 
Diagnosis status    
In breast only 146 (69%) 35 (76%) 111 (67%) 
In breast and 65 (31%) 11 (24%) 54 (33%) 
lymph nodes    
AET therapy:    
Tamoxifen 125 (59%) 35 (76%) 90 (55%) 
Aromatase 79 (37%) 9 (20%) 70 (42%) 
Inhibitors    
  2 (4%) 5 (3%) 
Not sure 7 (3%)   
Switched type of 23 (11%) 7 (14%) 15 (9%) 
AET taken    
Date started:    
2009 5 (2%) 1 (2%) 4 (2%) 
2010 54 (26%) 17 (30%) 37 (22%) 
2011 110 (52%) 18 (32%) 92 (56%) 
2012 42 (20%) 10 (22%) 32 (19%) 
Table  3.   Factor structure obtained by principal components analysis of the BMQ-AET 
specific items (highest factor loading indicated in emboldened text) 
 Factor 1 Factor 2 
 
Specific-Concerns 
  
I sometimes worry about 
long term effects of taking 
hormone treatment 
.848 -.242 
Having to  take hormone 
treatment  worries me 
.863 -.201 
I sometimes worry about 
having  hormone 
treatment 
over a long period of time 
.890 -.212 
Taking  hormone treatment 
disrupts  my life 
.658 -.023 
Hormone  treatment is a 
mystery to me 
.283 -.011 
Specific-Necessity   
Taking  hormone treatment 
makes me feel I am taking 
positive steps to remain 
well 
-.484 .541 
Without taking hormone 
treatment I would be more 
likely to develop breast 
cancer again 
-.157 .734 
My health at present  depends 
on me taking hormone 
treatment 
-.001 .784 
Hormone  treatment protects 
me from becoming ill 
-.161 .781 
My health in the future will 
depend on me taking 
hormone treatment 
-.128 .817 
TOTAL VARIANCE 
EXPLAINED 
35.375 21.562 
 
